LIR 生命科学发现,在小鼠体内和注射中,有皮肤喷洒的微硫化物减少了血糖,这是无针糖尿病治疗的一个很有希望的步骤。 LIR Life Sciences found a skin-applied semaglutide reduced blood sugar in mice as well as injections, a promising step for needle-free diabetes treatment.

LIR生命科学报告了积极的临床前临床结果，显示一种使用细胞穿透肽的无针外用司美格鲁肽配方有效降低了小鼠的血糖，与注射用司美格鲁肽在葡萄糖耐量测试中相匹配。 LIR Life Sciences reported positive interim preclinical results showing a needle-free, topical semaglutide formulation using cell-penetrating peptides effectively lowered blood glucose in mice, matching injectable semaglutide in glucose tolerance tests. 眼科治疗减少了葡萄糖刺塞,加速恢复到基线水平,表明通过皮肤提供有效药物。 The topical treatment reduced glucose spikes and accelerated return to baseline, indicating functional drug delivery through the skin. 这些调查结论支持了该公司用于大型peptide疗法的转基因平台,有可能应用于糖尿病和肥胖症治疗。 These findings support the company’s transdermal platform for large peptide therapies, with potential applications in diabetes and obesity treatment. 研究结果是初步的,尚未在人类中得到确认。 The results are preliminary and not yet confirmed in humans.